PRESS RELEASE

BiOkuris Announces Positive Results from Pivotal IBS Study (Vitabiotic) Evaluating BK002
Synbiotic formulation demonstrates dual therapeutic effect on gastrointestinal symptoms and anxiousness

Key Highlights

- ***BK002 achieved an 83% responder rate.***
- ***A significant alleviation of gastrointestinal symptoms in IBS patients.***
- ***A significant reduction in anxiousness.***

Herstal, Belgium – September 3, 2025: BiOkuris today announced positive topline results from its pivotal clinical study, Vitabiotic, evaluating BK002, the company's synbiotic formulation for the treatment of Irritable Bowel Syndrome (IBS).

The multi-center, double-blind, randomized controlled trial met all its clinical endpoints, with a 83% responder rate, BK002 also showed a **dual effect**: significant **relief of gastrointestinal symptoms and meaningful reduction in anxiousness**. These findings highlight the importance of targeting the gut–brain axis in IBS.

"BK002 offers a unique dual benefit—relieving gastrointestinal symptoms while reducing anxiousness," said **François Blondel, CEO of BiOkuris**. "These results validate our technology and demonstrate a new approach to IBS treatment that addresses both physical and psychological aspects of the disease."

Benoit Palms, Chief Business Officer, added: "The Vitabiotic study provides strong clinical validation for BK002. The very high responder rate and its dual effect distinguishes it from existing therapies, and we are now actively seeking strategic partners to bring this innovative product to market in 2026."

BK002 is a **patented synbiotic combination** of fungal chitin-glucan, the probiotic strain *Lactobacillus acidophilus* NCFM®, and vitamin D3. This multi-component formulation targets gastrointestinal function while engaging the gut–brain axis, offering a comprehensive approach to IBS management.

IBS affects an estimated 10–20% of the global population, yet more than 60% of patients remain dissatisfied with current treatment options. BK002 addresses this unmet need through its multi-component mechanism, supporting gut function, reinforcing the intestinal barrier, and improving psychological well-being.

About the Vitabiotic Study
The Vitabiotic study (NCT05780749) was a 12-week, prospective, randomized, double-blind,

placebo-controlled trial conducted in Belgium. After a 2-week run-in, patients received either BK002 or placebo for 8 weeks. Responders were re-randomized to continue BK002 or switch to placebo, while non-responders continued BK002 for another 4 weeks. All patients then entered a 4-week follow-up with free access to BK002. The study evaluated improvements in overall IBS symptoms, psychological well-being, and safety, confirming the dual effects observed with BK002.

About BiOkuris

BiOkuris is a biotech company specializing in innovative solutions for gastrointestinal health. With a strong focus on research and development, the company is dedicated to addressing unmet medical needs through cutting-edge products and therapies. Founded in 2021, BiOkuris has been investing in the development of combination products around the proprietary core technology chitin-glucan (CG) and chitosan. Both are biopolymers derived from the cell walls of *Aspergillus niger* with a strong potential to transform gastrointestinal healthcare[3]. For more information about BiOkuris, please visit www.biokuris.com

---

For more information

For media inquiries, please contact: Dr. Benoit Palms, Chief Business Officer info@biokuris.com
BiOkuris, Parc Industriel des Hauts Sarts – Zone 2 – 680, rue de Milmorts – 4040 Herstal – Belgium

---